| Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers DJ M. Lancaster-Smith, M. Jaderberg Gut 32, 252-255, 1991 | 210 | 1991 |
| Phase I study with ONCOS-102 for the treatment of solid tumors–an evaluation of clinical response and exploratory analyses of immune markers T Ranki, S Pesonen, A Hemminki, K Partanen, K Kairemo, T Alanko, ... Journal for immunotherapy of cancer 4, 1-18, 2016 | 193 | 2016 |
| Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model L Kuryk, ASW Møller, M Jaderberg Oncoimmunology 8 (2), e1532763, 2019 | 100 | 2019 |
| Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at … L Vassilev, T Ranki, T Joensuu, E Jäger, J Karbach, C Wahle, K Partanen, ... Oncoimmunology 4 (7), e1017702, 2015 | 57 | 2015 |
| Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type … T Ranki, T Joensuu, E Jäger, J Karbach, C Wahle, K Kairemo, T Alanko, ... Oncoimmunology 3 (10), e958937, 2014 | 56 | 2014 |
| A meta-analysis of the use of amoxycillin-clavulanic acid in surgical prophylaxis APR Wilson, S Shrimpton, M Jaderberg Journal of Hospital Infection 22, 9-21, 1992 | 47 | 1992 |
| Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma L Kuryk, ASW Møller, M Jaderberg Journal of medical virology 91 (9), 1702-1706, 2019 | 40 | 2019 |
| Antitumor‐specific T‐cell responses induced by oncolytic adenovirus ONCOS‐102 (AdV5/3‐D24‐GM‐CSF) in peritoneal mesothelioma mouse model L Kuryk, ASW Møller, M Garofalo, V Cerullo, S Pesonen, R Alemany, ... Journal of Medical Virology 90 (10), 1669-1673, 2018 | 40 | 2018 |
| Pilot study of ONCOS-102 and pembrolizumab: remodeling of the tumor microenvironment and clinical outcomes in anti–PD-1–resistant advanced melanoma AN Shoushtari, AJ Olszanski, M Nyakas, TJ Hornyak, JD Wolchok, ... Clinical Cancer Research 29 (1), 100-109, 2023 | 29 | 2023 |
| Maintenance treatment of duodenal ulceration-ranitidine 300mg at night is better than 150mg in cigarette smokers J Lee, Hardman Gut 32, 151-153, 1991 | 26 | 1991 |
| The cost effectiveness of amoxicillin/clavulanic acid as antibacterial prophylaxis in abdominal and gynaecological surgery PG Davey, SE Parker, IK Crombie, M Jaderberg Pharmacoeconomics 7, 347-356, 1995 | 23 | 1995 |
| A comparison of the costs of ceftazidime therapy and gentamicin combinations in three UK hospitals M Malek, W Lynch, N Wells, T Elliott, A Bint, P Sanderson, M Jaderberg, ... Journal of Antimicrobial Chemotherapy 29 (2), 207-217, 1992 | 20 | 1992 |
| Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401 L Kuryk, ASW Møller, M Jaderberg Cancer gene therapy 26 (1), 26-31, 2019 | 18 | 2019 |
| Optimization of early steps in oncolytic adenovirus ONCOS-401 production in T-175 and HYPERFlasks L Kuryk, ASW Møller, A Vuolanto, S Pesonen, M Garofalo, V Cerullo, ... International Journal of Molecular Sciences 20 (3), 621, 2019 | 16 | 2019 |
| 361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma–12 month analysis of … M Jaderberg, S Cedres, L Paz-Ares, X Serres, C Ricordel, N Isambert, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 11 | 2020 |
| The pharmaceutical industry—a key partner in providing information to the patient and a key player in the European debate on direct to consumer communication M Jaderberg Journal of Medical Marketing 2 (2), 179-183, 2002 | 10 | 2002 |
| Phase I/II study to evaluate systemic durvalumab+ intraperitoneal (IP) ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal … D Zamarin, K Odunsi, BM Slomovitz, LR Duska, JJ Nemunaitis, M Reilley, ... Journal of Clinical Oncology 38 (15_suppl), 3017-3017, 2020 | 6 | 2020 |
| 1083P A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma AN Shoushtari, AJ Olszanski, M Nyakas, TJ Hornyak, JD Wolchok, ... Annals of Oncology 32, S897-S898, 2021 | 5 | 2021 |
| ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: A randomized phase 2 study investigating clinical outcomes and the tumor microenvironment S Ponce, S Cedrés, C Ricordel, N Isambert, S Viteri, M Herrera-Juarez, ... Journal for immunotherapy of cancer 11 (9), 2023 | 4 | 2023 |
| Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer … D Zamarin, K Odunsi, E Zsiros, BM Slomovitz, A Pimentel, LR Duska, ... Journal of Clinical Oncology 40 (16_suppl), 2600-2600, 2022 | 4 | 2022 |
